Speaker Profile

PHARM.D., Dean and Distinguished Professor, College of Pharmacy, University of Florida

Biography
An internationally-recognized leader in pharmacogenomics and genomic medicine, with over 300 peer-reviewed publications and over $50M in research funding as principal investigator. In 2015, 2016, 2017, and 2018 she was named a Clarivate Analytics Highly Cited Researcher, indicating the top 1% of most highly cited scientists globally in the previous decade. Had numerous service roles, including the NIH, FDA, CDC, American Heart Association, American College of Clinical Pharmacy (ACCP), and ASCPT. Served as President in 2016-17. Dr. Johnson received numerous awards: Elected to the National Academy of Medicine, inducted as a Fellow of the American Association for the Advancement of Science and fellowship in three other societies, recipient of Leon I Goldberg Young Investigator Award (ASCPT), Volwiler Research Achievement Award from American Association of Colleges of Pharmacy (AACP) (2007), Therapeutic Frontiers Award, Paul Parker Medal (ACCP), the ASCPT Rawls Palmer Progress in Medicine Award, the PMWC Luminary Award, among others.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB